Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Ayse T. Kendi"'
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Metastatic prostate cancer continues to be an incurable disease. Despite all the novel therapies approved in the past two decades, overall patient outcomes remain relatively poor, and these patients die on a regular basis. Clearly, improvements in cu
Externí odkaz:
https://doaj.org/article/20b86f12d2fe41ef9d6281df5626c054
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 14, p 11626 (2023)
Radiopharmaceuticals are rapidly developing as a field, with the successful use of targeted beta emitters in neuroendocrine tumors and prostate cancer serving as catalysts. Targeted alpha emitters are in current development for several potential onco
Externí odkaz:
https://doaj.org/article/e446452a1e7a48e59337b40c2558ef49
Autor:
Jamal Alamiri, Cameron J. Britton, Mohamed E. Ahmed, Jack R. Andrews, Julianna L. Higa, Ayca Dundar, R. Jeffrey Karnes, Eugene Kwon, Val J. Lowe, Ayse T. Kendi, Michael S. Bold, Lance C. Pagliaro
Publikováno v:
The Prostate. 82:1483-1490
Prostatic specific antigen (PSA) has well-recognized limitations as a marker for treatment response and disease progression. Post hoc analysis of the PREVAIL trial reported 24.5% of chemotherapy naïve metastatic castration-resistant prostate cancer
Autor:
Ensign, MD, PhD Shannon Fortin, MD Muskan Agarwal, PhD Molly Klanderman, MB, BCh Mohamed Badawy, MD Thorvardur R. Halfdanarson, MD Derek R. Johnson, Sonbol, MD Mohamad Bassam, MD Ayse T. Kendi
Publikováno v:
Nuclear Medicine Communications.
Autor:
Phillip H. Kuo, Don C. Yoo, Ryan Avery, Marc Seltzer, Jeremie Calais, James Nagarajah, Wolfgang A. Weber, Wolfgang P. Fendler, Michael S. Hofman, Bernd J. Krause, Marcia Brackman, Euloge Kpamegan, Samson Ghebremariam, Taylor Benson, Ana M. Catafau, Ayse T. Kendi
Publikováno v:
Journal of Nuclear Medicine. :265077
Autor:
Jeremie Calais, Stephen M. Eulau, Linda Gardner, Ralph J. Hauke, Ayse T. Kendi, Neal D. Shore, Song Zhao
Publikováno v:
Cancer Treatment Reviews. 115:102524
Autor:
Mohamed E. Ahmed, Jack R. Andrews, Ahmed Mahmoud, Matthew Lee, Daniel S Childs, Ayse T. Kendi, Geoffrey Johnson, Matthew K. Tollefson, Stephen A. Boorjian, R. Jeffrey Karnes, Eugene D. Kwon
Publikováno v:
Journal of Clinical Oncology. 41:269-269
269 Background: Metastatic visceral involvement in prostate cancer patients conveys a poor prognosis. Survival patterns of site-specific visceral metastasis are poorly understood. Here, we sought to investigate survival patterns in prostate cancer pa
Publikováno v:
Journal of Clinical Oncology. 41:59-59
59 Background: Radium-223 (Ra-223) has been approved for the treatment of metastatic castration resistant prostate cancer (mCRPC) with predominantly osseous metastases. PSA flare phenomenon with Ra-223 limits the use of PSA as a prognostic tool to pr
Autor:
Kelly Lehner, Mohamed E. Ahmed, Raevti Bole, Jack R. Andrews, Rimki Haloi, Michael S. Bold, Ayse T. Kendi, R. Jeffrey Karnes, Eugene D. Kwon, Alan Haruo Bryce
Publikováno v:
Journal of Clinical Oncology. 41:192-192
192 Background: In the setting of disease progression of metastatic castrate resistant prostate cancer (mCRPC) on docetaxel, abiraterone acetate (AA) and enzalutamide are two commonly used second line therapies with data demonstrating survival benefi
Autor:
Kelly Lehner, Mohamed E. Ahmed, Raevti Bole, Jack R. Andrews, Rimki Haloi, Michael S. Bold, Ayse T. Kendi, R. Jeffrey Karnes, Eugene D. Kwon, Alan Haruo Bryce
Publikováno v:
Journal of Clinical Oncology. 41:189-189
189 Background: The objective of this study is to evaluate the prognostic value of early PSA decline following initiation of second-generation hormone therapy (2nd HT), namely abiraterone acetate or enzalutamide, in the post-chemotherapy setting in p